
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics has demonstrated a significant increase in median frataxin (FXN) expression, rising from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, markedly exceeding the performance seen in healthy volunteers. Additionally, the company's lead product candidate shows a median improvement of -2.20 points in the modified Friedreich’s Ataxia Rating Scale (mFARS), contrasting favorably with a decline of +1.00 points observed in the FACOMS natural history population over the same period. These compelling efficacy data highlight the potential of Larimar's innovative CPP technology to provide meaningful therapeutic benefits for patients with Friedreich's ataxia, supporting a positive outlook for the company's stock performance.
Bears say
Larimar Therapeutics Inc. is facing a negative outlook due to its significant revision of future revenue estimates, with projections for FY29 decreasing from $659 million to $407 million, indicating potential challenges in achieving market penetration within the Friedreich's ataxia (FA) market. The company's lead product candidate, CTI-1601, shows concerning clinical trial results, notably a median mFARS change of -2.20 points, which contrasts with a +1.00 point decline in the FACOMS natural history population, raising questions about its efficacy. Additionally, the expected market share of approximately 25% may not be sufficient to sustain confidence in the company's growth trajectory given these data points.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares